JP2013542935A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2013542935A5 JP2013542935A5 JP2013532925A JP2013532925A JP2013542935A5 JP 2013542935 A5 JP2013542935 A5 JP 2013542935A5 JP 2013532925 A JP2013532925 A JP 2013532925A JP 2013532925 A JP2013532925 A JP 2013532925A JP 2013542935 A5 JP2013542935 A5 JP 2013542935A5
- Authority
- JP
- Japan
- Prior art keywords
- ornithine
- salt
- benzoate
- ppm
- less
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000000034 method Methods 0.000 claims 33
- 239000000203 mixture Substances 0.000 claims 15
- OPWXRPAHCDZTNU-VWMHFEHESA-N benzoic acid;(2s)-2,5-diaminopentanoic acid Chemical compound NCCC[C@H](N)C(O)=O.OC(=O)C1=CC=CC=C1 OPWXRPAHCDZTNU-VWMHFEHESA-N 0.000 claims 11
- AHLPHDHHMVZTML-BYPYZUCNSA-N L-Ornithine Chemical class NCCC[C@H](N)C(O)=O AHLPHDHHMVZTML-BYPYZUCNSA-N 0.000 claims 10
- WLJVXDMOQOGPHL-UHFFFAOYSA-N phenylacetic acid Chemical class OC(=O)CC1=CC=CC=C1 WLJVXDMOQOGPHL-UHFFFAOYSA-N 0.000 claims 8
- 150000003839 salts Chemical class 0.000 claims 8
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims 6
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 claims 6
- 239000002904 solvent Substances 0.000 claims 6
- LRSYFEZBIMVWRY-VWMHFEHESA-N (2s)-2,5-diaminopentanoic acid;2-phenylacetic acid Chemical compound NCCC[C@H](N)C(O)=O.OC(=O)CC1=CC=CC=C1 LRSYFEZBIMVWRY-VWMHFEHESA-N 0.000 claims 5
- -1 alkali metal alkoxides Chemical class 0.000 claims 4
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 claims 3
- 229910052783 alkali metal Inorganic materials 0.000 claims 3
- 239000002585 base Substances 0.000 claims 3
- 229910052709 silver Inorganic materials 0.000 claims 3
- 239000004332 silver Substances 0.000 claims 3
- GGTYBZJRPHEQDG-WCCKRBBISA-N (2s)-2,5-diaminopentanoic acid hydrochloride Chemical group Cl.NCCC[C@H](N)C(O)=O GGTYBZJRPHEQDG-WCCKRBBISA-N 0.000 claims 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims 2
- 150000001450 anions Chemical class 0.000 claims 2
- 150000001558 benzoic acid derivatives Chemical class 0.000 claims 2
- 150000001768 cations Chemical class 0.000 claims 2
- 230000001747 exhibiting effect Effects 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 239000003279 phenylacetic acid Substances 0.000 claims 2
- 229960003424 phenylacetic acid Drugs 0.000 claims 2
- 238000000634 powder X-ray diffraction Methods 0.000 claims 2
- CLDWGXZGFUNWKB-UHFFFAOYSA-M silver;benzoate Chemical group [Ag+].[O-]C(=O)C1=CC=CC=C1 CLDWGXZGFUNWKB-UHFFFAOYSA-M 0.000 claims 2
- 229910052708 sodium Inorganic materials 0.000 claims 2
- 239000011734 sodium Substances 0.000 claims 2
- INIRLMDMLPBYJS-SCGRZTRASA-N (2S)-2,5-diaminopentanoic acid hydrochloride Chemical compound Cl.NCCC[C@H](N)C(O)=O.NCCC[C@H](N)C(O)=O INIRLMDMLPBYJS-SCGRZTRASA-N 0.000 claims 1
- UIQPERPLCCTBGX-UHFFFAOYSA-N 2-phenylacetic acid;silver Chemical compound [Ag].OC(=O)CC1=CC=CC=C1 UIQPERPLCCTBGX-UHFFFAOYSA-N 0.000 claims 1
- ITIONVBQFUNVJV-UHFFFAOYSA-N Etomidoline Chemical group C12=CC=CC=C2C(=O)N(CC)C1NC(C=C1)=CC=C1OCCN1CCCCC1 ITIONVBQFUNVJV-UHFFFAOYSA-N 0.000 claims 1
- FOIXSVOLVBLSDH-UHFFFAOYSA-N Silver ion Chemical compound [Ag+] FOIXSVOLVBLSDH-UHFFFAOYSA-N 0.000 claims 1
- IPBVNPXQWQGGJP-UHFFFAOYSA-N acetic acid phenyl ester Natural products CC(=O)OC1=CC=CC=C1 IPBVNPXQWQGGJP-UHFFFAOYSA-N 0.000 claims 1
- 150000008044 alkali metal hydroxides Chemical class 0.000 claims 1
- CLLNPYSXOIKTLL-UHFFFAOYSA-L disilver diacetate Chemical compound [Ag+].[Ag+].CC([O-])=O.CC([O-])=O CLLNPYSXOIKTLL-UHFFFAOYSA-L 0.000 claims 1
- 229940049953 phenylacetate Drugs 0.000 claims 1
- 229940006198 sodium phenylacetate Drugs 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US39058510P | 2010-10-06 | 2010-10-06 | |
| US61/390,585 | 2010-10-06 | ||
| PCT/US2011/054983 WO2012048043A1 (en) | 2010-10-06 | 2011-10-05 | Methods of making l-ornithine phenyl acetate |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2013542935A JP2013542935A (ja) | 2013-11-28 |
| JP2013542935A5 true JP2013542935A5 (enExample) | 2014-11-20 |
| JP6087284B2 JP6087284B2 (ja) | 2017-03-01 |
Family
ID=45928120
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013532925A Expired - Fee Related JP6087284B2 (ja) | 2010-10-06 | 2011-10-05 | Ｌ−オルニチンフェニルアセテートを製造するための方法 |
Country Status (16)
| Country | Link |
|---|---|
| US (2) | US8946473B2 (enExample) |
| EP (1) | EP2625162B1 (enExample) |
| JP (1) | JP6087284B2 (enExample) |
| KR (1) | KR101888215B1 (enExample) |
| CN (1) | CN103502203B (enExample) |
| AU (1) | AU2011312042B2 (enExample) |
| BR (1) | BR112013008054B1 (enExample) |
| CA (1) | CA2813563C (enExample) |
| EA (1) | EA028395B1 (enExample) |
| ES (1) | ES2720148T3 (enExample) |
| IL (1) | IL225512A (enExample) |
| MX (1) | MX360062B (enExample) |
| NZ (1) | NZ609191A (enExample) |
| SG (1) | SG189231A1 (enExample) |
| TR (1) | TR201903978T4 (enExample) |
| WO (1) | WO2012048043A1 (enExample) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP5116479B2 (ja) | 2004-11-26 | 2013-01-09 | ユーシーエル ビジネス ピーエルシー | オルニチンならびにフェニルアセテートまたはフェニルブチレートを含む、肝性脳症を治療するための組成物 |
| ES2928586T3 (es) | 2009-04-03 | 2022-11-21 | Ocera Therapeutics Inc | Fenilacetato de L-ornitina y métodos para elaborar el mismo |
| KR101715008B1 (ko) | 2009-06-08 | 2017-03-22 | 유씨엘 비즈니스 피엘씨 | Ｌ―오르니틴 페닐아세테이트를 사용한 문맥압 항진증의 치료 및 간 기능 회복 |
| JP6087284B2 (ja) | 2010-10-06 | 2017-03-01 | オセラ セラピューティクス， インコーポレイテッド | Ｌ−オルニチンフェニルアセテートを製造するための方法 |
| DK3223829T3 (da) | 2014-11-24 | 2020-02-10 | Ucl Business Ltd | Behandling af sygdomme associeret med hepatisk stellat-celleaktivering under anvendelse af ammoniak-sænkende terapier |
| RU2755904C2 (ru) * | 2015-04-20 | 2021-09-22 | Осера Терапьютикс, Инк. | Составы l-орнитин фенилацетата |
| HK1249434A1 (zh) * | 2015-08-18 | 2018-11-02 | Ocera Therapeutics, Inc. | 使用与苯乙酸盐和苯丁酸盐中的至少一种组合的l-鸟氨酸治疗和预防肌肉损失 |
| US11219611B2 (en) | 2015-11-13 | 2022-01-11 | Ocera Therapeutics, Inc. | Formulations of L-ornithine phenylacetate |
| MX389926B (es) * | 2015-11-13 | 2025-03-20 | Ocera Therapeutics Inc | Formulaciones de fenilacetato de l-ornitina |
| JOP20190146A1 (ar) | 2016-12-19 | 2019-06-18 | Axcella Health Inc | تركيبات حمض أميني وطرق لمعالجة أمراض الكبد |
| CA3063134A1 (en) * | 2017-05-11 | 2018-11-15 | Ocera Therapeutics, Inc. | Processes of making l-ornithine phenylacetate |
| BR112020002419A2 (pt) | 2017-08-14 | 2020-07-28 | Axcella Health Inc. | aminoácido para o tratamento de doença do fígado |
| WO2019246225A1 (en) | 2018-06-20 | 2019-12-26 | Axcella Health Inc. | Compositions and methods for the treatment of fat infiltration in muscle |
| MX2021013526A (es) | 2019-05-09 | 2021-12-10 | Ocera Therapeutics Inc | Metodos de evaluacion y tratamiento de encefalopatia hepatica. |
| WO2024261477A1 (en) | 2023-06-20 | 2024-12-26 | Yaqrit Limited | Combination of tlr4 antagonist, ornithine and phenylacetate or phenylbutyrate |
Family Cites Families (45)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB965637A (en) | 1962-04-23 | 1964-08-06 | Tanabe Seiyaku Co | L-ornithine l-aspartate |
| NL302572A (enExample) | 1962-12-27 | |||
| GB1067742A (en) | 1963-09-16 | 1967-05-03 | Kyowa Hakko Kogyo Kk | Process for the preparation of l-ornithine l-aspartate |
| ZA716628B (en) | 1970-10-15 | 1972-06-28 | Richardson Merrell Spa | Composition and method for treatment of hepatic disease and mental fatigue |
| US4100293A (en) | 1974-04-15 | 1978-07-11 | The Johns Hopkins University | Treatment of hepatic disorders with therapeutic compositions comprising keto analogs of essential amino acids |
| US3950529A (en) | 1975-02-03 | 1976-04-13 | Massachusetts General Hospital | Amino acid formulations for patients with liver disease and method of using same |
| US4320146A (en) | 1978-03-17 | 1982-03-16 | The Johns Hopkins University | Treatment of hepatic and renal disorders with ornithine and arginine salts of branched chain keto acids |
| US4228099A (en) | 1978-03-17 | 1980-10-14 | The Johns Hopkins University | Ornithine and arginine salts of branched chain keto acids and uses in treatment of hepatic and renal disorders |
| US4352814A (en) | 1979-04-18 | 1982-10-05 | The Johns Hopkins University | Treatment of hepatic and renal disorders with mixed salts of essential or semi-essential amino acids and nitrogen-free analogs |
| US4284647A (en) | 1980-03-31 | 1981-08-18 | The Johns Hopkins University | Process for waste nitrogen removal |
| US4457942A (en) | 1982-08-20 | 1984-07-03 | Brusilow Saul W | Process for waste nitrogen removal |
| DE4020980C1 (enExample) | 1990-07-02 | 1991-09-26 | Degussa Ag, 6000 Frankfurt, De | |
| US5591613A (en) | 1990-07-02 | 1997-01-07 | Degussa Aktiengesellschaft | Method for the preparation of D-arginine and L-ornithine |
| JP3127484B2 (ja) | 1991-02-28 | 2001-01-22 | 味の素株式会社 | 肝炎治療薬 |
| US5767086A (en) | 1992-04-03 | 1998-06-16 | Terrapin Technologies, Inc. | Bone marrow stimulation by certain glutathione analogs |
| EP0659150B1 (en) | 1992-09-09 | 1997-05-21 | FISONS plc | Pharmaceutical packaging |
| US5571783A (en) | 1993-03-09 | 1996-11-05 | Clintec Nutrition Company | Composition and method for treating patients with hepatic disease |
| JP3273578B2 (ja) * | 1993-09-21 | 2002-04-08 | 第一化学薬品株式会社 | オルニチンと酸性アミノ酸類又はケト酸類との塩の製造法 |
| US5856481A (en) | 1994-07-28 | 1999-01-05 | Syntex (U.S.A.) Inc. | 2-(2-amino-1,6-dihydro-6-oxo-purin-9-yl)methoxy-1,3-propanediol derivative |
| WO1997030167A1 (en) | 1996-02-13 | 1997-08-21 | The Trustees Of The University Of Pennsylvania | Method of treating liver disorders |
| ZA986614B (en) | 1997-07-25 | 1999-01-27 | Gilead Sciences | Nucleotide analog composition |
| GB9815567D0 (en) | 1998-07-18 | 1998-09-16 | Glaxo Group Ltd | Antiviral compound |
| US6258849B1 (en) | 1998-07-23 | 2001-07-10 | Stanislaw R. Burzynski | Treatment regimen for administration of phenylacetylglutamine, phenylacetylisoglutamine, and/or phenylacetate |
| CA2374273A1 (en) | 1999-05-21 | 2000-11-30 | Takeda Chemical Industries, Ltd. | Liver function controlling agents |
| US6768024B1 (en) | 2000-08-04 | 2004-07-27 | Lion Bioscience Ag | Triamine derivative melanocortin receptor ligands and methods of using same |
| JP3211824B1 (ja) | 2000-10-26 | 2001-09-25 | 味の素株式会社 | 分岐鎖アミノ酸含有医薬用顆粒製剤とその製造方法 |
| TWI309162B (en) | 2001-03-15 | 2009-05-01 | Rikagaku Kenkyusho | Amino acid composition for improving functional disorder of liver |
| US6503530B1 (en) | 2001-11-01 | 2003-01-07 | Chunghee Kimberly Kang | Method of preventing development of severe metabolic derangement in inborn errors of metabolism |
| US20030105104A1 (en) | 2001-11-27 | 2003-06-05 | Burzynski Stanislaw R. | Formulation of amino acids and riboflavin useful to reduce toxic effects of cytotoxic chemotherapy |
| US20030195255A1 (en) | 2002-04-12 | 2003-10-16 | Summar Marshall L. | Method for treating hepatic encephalopathies |
| US20040229948A1 (en) | 2002-04-12 | 2004-11-18 | Summar Marshall L. | Method for preventing hepatic encephalopathic episodes |
| CN1383815A (zh) | 2002-05-08 | 2002-12-11 | 刘万忠 | 防治肝病、肝性脑病的鸟氨酸和门冬氨酸的复方制剂及其制备方法 |
| US20040152784A1 (en) | 2002-07-23 | 2004-08-05 | Special Products Limited | Pharmaceutical composition and method for treatment of a urea cycle deficiency or sickle-cell anaemia |
| AU2003261825A1 (en) | 2002-08-30 | 2004-03-19 | Ajinomoto Co., Inc. | Therapeutic agent for hepatic disease |
| US20050059150A1 (en) | 2003-09-17 | 2005-03-17 | Becton, Dickinson And Company | Environments that maintain function of primary liver cells |
| MXPA03009902A (es) * | 2003-10-29 | 2005-05-03 | Manuel Francisco Lara Och Jose | Compuestos para reducir la hiperamonemia en pacientes con cirrosis u otras incapacidad para la eliminacion de amonio. |
| CA2556752C (en) | 2004-02-23 | 2016-02-02 | Genentech, Inc. | Heterocyclic self-immolative linkers and conjugates |
| JP4954867B2 (ja) | 2004-05-06 | 2012-06-20 | オステオロジックス エイ／エス | 有機金属塩類を製造するための高収率で迅速な合成法 |
| WO2006059237A1 (en) | 2004-08-30 | 2006-06-08 | Lunamed, Inc. | 4-phenylbutyric acid controlled-release formulations for therapeutic use |
| JP5116479B2 (ja) | 2004-11-26 | 2013-01-09 | ユーシーエル ビジネス ピーエルシー | オルニチンならびにフェニルアセテートまたはフェニルブチレートを含む、肝性脳症を治療するための組成物 |
| RS53324B (sr) | 2005-11-17 | 2014-10-31 | Silverstone Pharma Est. | Stabilna formulacija amorfnih soli perindoprila, postupak za njihovu pripremu, naročito industrijsku pripremu, i njihova upotreba u terapiji hipertenzije |
| CN201421432Y (zh) * | 2009-02-20 | 2010-03-10 | 山东师范大学 | 一种相干衍射成像处理装置 |
| ES2928586T3 (es) * | 2009-04-03 | 2022-11-21 | Ocera Therapeutics Inc | Fenilacetato de L-ornitina y métodos para elaborar el mismo |
| KR101715008B1 (ko) | 2009-06-08 | 2017-03-22 | 유씨엘 비즈니스 피엘씨 | Ｌ―오르니틴 페닐아세테이트를 사용한 문맥압 항진증의 치료 및 간 기능 회복 |
| JP6087284B2 (ja) | 2010-10-06 | 2017-03-01 | オセラ セラピューティクス， インコーポレイテッド | Ｌ−オルニチンフェニルアセテートを製造するための方法 |
-
2011
- 2011-10-05 JP JP2013532925A patent/JP6087284B2/ja not_active Expired - Fee Related
- 2011-10-05 NZ NZ609191A patent/NZ609191A/en not_active IP Right Cessation
- 2011-10-05 WO PCT/US2011/054983 patent/WO2012048043A1/en not_active Ceased
- 2011-10-05 ES ES11831546T patent/ES2720148T3/es active Active
- 2011-10-05 KR KR1020137011664A patent/KR101888215B1/ko active Active
- 2011-10-05 MX MX2013003764A patent/MX360062B/es active IP Right Grant
- 2011-10-05 CA CA2813563A patent/CA2813563C/en active Active
- 2011-10-05 CN CN201180058441.1A patent/CN103502203B/zh not_active Expired - Fee Related
- 2011-10-05 SG SG2013024559A patent/SG189231A1/en unknown
- 2011-10-05 AU AU2011312042A patent/AU2011312042B2/en not_active Ceased
- 2011-10-05 US US13/878,146 patent/US8946473B2/en active Active
- 2011-10-05 BR BR112013008054-0A patent/BR112013008054B1/pt not_active IP Right Cessation
- 2011-10-05 EA EA201390403A patent/EA028395B1/ru not_active IP Right Cessation
- 2011-10-05 TR TR2019/03978T patent/TR201903978T4/tr unknown
- 2011-10-05 EP EP11831546.4A patent/EP2625162B1/en active Active
-
2013
- 2013-04-02 IL IL225512A patent/IL225512A/en active IP Right Grant
-
2015
- 2015-01-21 US US14/601,591 patent/US9260379B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2013542935A5 (enExample) | ||
| JP2012522803A5 (enExample) | ||
| WO2014043706A8 (en) | Method of synthesizing thyroid hormone analogs and polymorphs thereof | |
| WO2016014927A3 (en) | Crystalline form of nicotinamide riboside | |
| SI2902384T1 (en) | The form of ivabradine hydrochloride | |
| JP2014506554A5 (enExample) | ||
| JP2014512451A5 (enExample) | ||
| JP2015500843A5 (enExample) | ||
| NZ609191A (en) | Methods of making l-ornithine phenyl acetate | |
| JP2015510010A5 (enExample) | ||
| JP2013522367A5 (enExample) | ||
| WO2015011119A3 (en) | Salts of dasatinib in amorphous form | |
| WO2012138147A3 (en) | 1-(3-cyano-1-isopropyl-indol-5-yl)pyrazole-4-carboxylic acid crystalline form and the producing method thereof | |
| WO2013121235A3 (en) | Process for preparation of dronedarone by removal of hydroxyl group | |
| JP2012233159A5 (enExample) | ||
| CA2899024C (en) | Crystalline forms of {[1-cyano-5-(4-chlorophenoxy)-4-hydroxy-isoquinoline-3-carbonyl]-amino}-acetic acid | |
| MX353863B (es) | Metodo para preparar una forma solida de acido acetico y productos de la misma. | |
| JP2012051888A5 (enExample) | ||
| WO2015044853A3 (en) | Process for preparation of dimethyl fumarate | |
| WO2013065070A8 (en) | Amorphous form of cabazitaxel and process for its preparation | |
| WO2012115402A3 (en) | Crystalline form of docetaxel and process for preparation thereof | |
| JP2014031512A5 (enExample) | ||
| MX2013000013A (es) | Forma cristalina delta de la sal de arginina de perindoprilo, su procedimiento de preparacion, y las composiciones farmaceuticas que la contienen. | |
| JP2013528577A5 (enExample) | ||
| WO2012078289A3 (en) | Nanowire preparation methods, compositions, and articles |